Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib vs vandetanib in Japanese patients with cancer
jRCT2080225186Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of selpercatinib in cancer (2 arms), sponsored by Eli Lilly and Company. Started May 2020; status: recruiting.
02
Drugs
selpercatinib
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080225186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225186.